I am not a pharma market analyst (thank God!) but it strikes me that a year on year 19% jump in revenue for a long established product is quite remarkable - in any market - another "coincidence" perhaps?
That's Q3 data 2021 - the Eliquis boom was also seen in Q2 - I happened to see it last summer ... 16% in Q2 if I recall - good time to be in pharma! ... keep an eye on dementia meds next? early onset cases are probably aggressively treated.
(please seek the advise of a competent financial advisor!)
Some related news from Pfizer - Sales of Eliquis - widely used blood thinning med (think: "clot-shot") >
"Sales of blood thinner Eliquis came in at $1.35 billion, a 19% increase on the third quarter of last year, "
https://www.fiercepharma.com/pharma/pfizer-ups-2021-covid-19-vaccine-sales-projection-to-36-billion-remains-coy-about-future
I am not a pharma market analyst (thank God!) but it strikes me that a year on year 19% jump in revenue for a long established product is quite remarkable - in any market - another "coincidence" perhaps?
That's proof that can't be denied but the usual suspects will. Great find.
That's Q3 data 2021 - the Eliquis boom was also seen in Q2 - I happened to see it last summer ... 16% in Q2 if I recall - good time to be in pharma! ... keep an eye on dementia meds next? early onset cases are probably aggressively treated.
(please seek the advise of a competent financial advisor!)